Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 32, 2013, Pages

  Merchant, Mark ^a   Ma, Xiaolei ^a,c   Maun, Henry R ^a   Zheng, Zhong ^a,d   Peng, Jing ^a   Romero, Mally ^a,e   Huang, Arthur ^a,f   Yang, Nai Ying ^a   Nishimura, Merry ^a   Greve, Joan ^a   Santell, Lydia ^a   Zhang, Yu Wen ^a   Su, Yanli ^a   Kaufman, Dafna W ^a   Billeci, Karen L ^a   Mai, Elaine ^a   Moffat, Barbara ^a   Lim, Amy ^a   Duenas, Eileen T ^a   Phillips, Heidi S ^a   Xiang, Hong ^a   Young, Judy C ^a   Vande Woude, George F ^a   Dennis, Mark S ^a   Reilly, Dorothea E ^b   Schwall, Ralph H ^a   Starovasnik, Melissa A ^a   Lazarus, Robert A ^a   Yansura, Daniel G ^a   more..

^a GENENTECH INC   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d Celgene Inc ^*

^e CELGENE CORPORATION   (United States)

^f RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

HGFR; MetMAb; OA5D5; Scatter factor

Indexed keywords

INTEGRIN; MONOCLONAL ANTIBODY; ONARTUZUMAB; PLEXIN; SCATTER FACTOR RECEPTOR; SEMAPHORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA CHAIN; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG STRUCTURE; ESCHERICHIA COLI; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TUMOR VOLUME;

HGFR; METMAB; OA5D5; SCATTER FACTOR;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; MICE, SCID; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; SEQUENCE HOMOLOGY, AMINO ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881405670     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1302725110     Document Type: Article

References (70)

1. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767-774.
2. Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69:373-398.
3. Niemann HH (2011) Structural insights into Met receptor activation. Eur J Cell Biol 90(11):972-981.
4. Ridgway JB, Presta LG, Carter P (1996) 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9(7):617-621.
5. Donate LE, et al. (1994) Molecular evolution and domain structure of plasminogenrelated growth factors (HGF/SF and HGF1/MSP). Protein Sci 3(12):2378-2394.
6. Hartmann G, et al. (1992) A functional domain in the heavy chain of scatter factor/ hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc Natl Acad Sci USA 89(23):11574-11578.
7. Lokker NA, et al. (1992) Structure-function analysis of hepatocyte growth factor: Identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 11(7):2503-2510.
8. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915-925.
9. Birchmeier C, Gherardi E (1998) Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8(10):404-410.
10. Neuss S, Becher E, Wöltje M, Tietze L, Jahnen-DechentW(2004) Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 22(3):405-414.
11. Huh CG, et al. (2004) Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101(13): 4477-4482.
12. Borowiak M, et al. (2004) Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA 101(29):10608-10613.
13. Chmielowiec J, et al. (2007) c-Met is essential for wound healing in the skin. J Cell Biol 177(1):151-162.
14. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 12(2):89-103.
15. Kong-Beltran M, Stamos J, Wickramasinghe D (2004) The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6(1):75-84.
16. Martens T, et al. (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12(20 Pt 1):6144-6152.
17. Jin H, et al. (2008) MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 68(11): 4360-4368.
18. Moss R, et al. (2010) Complete results from phase 1 dose escalation study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Ann Oncol 21(Suppl 8):viii165.
19. Spigel DR, et al. (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29(Suppl 15):477s.
20. Petrelli A, et al. (2006) Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 103(13):5090-5095.
21. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM (1998) Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 111(Pt 2):237-247.
22. Schwall RH, et al. (1996) Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J Cell Biol 133(3):709-718.
23. Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998) Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and αvβ3 integrins. Circulation 98(11):1085-1091.
24. Merchant AM, et al. (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16(7):677-681.
25. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C (1991) Sequences of proteins of Immunological Interest (Public Health Service, National Institute of Health, Bethesda, MD).
26. MacCallum RM, Martin AC, Thornton JM (1996) Antibody-antigen interactions: Contact analysis and binding site topography. J Mol Biol 262(5):732-745.
27. Simmons LC, et al. (2002) Expression of full-length immunoglobulins in Escherichia coli: Rapid and efficient production of aglycosylated antibodies. J Immunol Methods 263(1-2):133-147.
28. Rietsch A, Belin D, Martin N, Beckwith J (1996) An in vivo pathway for disulfide bond isomerization in Escherichia coli. Proc Natl Acad Sci USA 93(23):13048-13053.
29. Goebl NA, et al. (2008) Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 19(12):5490-5505.
30. Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93(11):5512-5516.
31. Radaev S, Sun PD (2001) Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem 276(19):16478-16483.
32. Bender BC, et al. (2008) Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb. EJS Suppl 6(12):170.
33. Xiang H, et al. (2008) Supporting MetMAb entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information. EJC Suppl 6(12):167.
34. Bai S, et al. (2011) Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, MetMAb, in patients with advanced solid tumors. J Clin Oncol 29(Suppl 15):182s.
35. Salgia R, et al. (2008) A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors. EJC Suppl 6(12):129.
36. Schneider SW, et al. (2004) Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 107(3):272-276.
37. de Vries NA, Beijnen JH, van Tellingen O (2009) High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev 35(8):714-723.
38. Rong S, et al. (1992) Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 12(11):5152-5158.
39. Bhargava M, et al. (1992) Scatter factor and hepatocyte growth factor: Activities, properties, and mechanism. Cell Growth Differ 3(1):11-20.
40. Zhang YW, et al. (2005) Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24(1):101-106.
41. Peschard P, et al. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8(5): 995-1004.
42. Kong-Beltran M, et al. (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66(1):283-289.
43. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372(3):774-797.
44. Lokker NA, Godowski PJ (1993) Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1. J Biol Chem 268(23): 17145-17150.
45. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C (2004) Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. EMBO J 23(12): 2325-2335.
46. Gunasekaran K, et al. (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG. J Biol Chem 285(25):19637-19646.
47. Muda M, et al. (2011) Therapeutic assessment of SEED: A new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 24(5):447-454.
48. Salgia R, et al. (2010) Complete results from a phase Ia dose-escalation and doseexpansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor Met, administered intravenously in patients with locally advanced or metastatic solid tumors. Cancer Res 70(8 Suppl):2774.
49. Jung ST, et al. (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci USA 107(2):604-609.
50. Niemann HH, et al. (2007) Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB. Cell 130(2):235-246.
51. Pacchiana G, et al. (2010) Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 285(46):36149-36157.
52. Mijares A, Lebesgue D, Wallukat G, Hoebeke J (2000) From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-β2- adrenoceptor antibody behave as antagonists. Mol Pharmacol 58(2):373-379.
53. Qian MD, et al. (2006) Novel agonist monoclonal antibodies activate TrkB receptors and demonstrate potent neurotrophic activities. J Neurosci 26(37):9394-9403.
54. Yu Y, Zhang S, Wang X, Yang Z, Ou G (2010) Overexpression of TrkB promotes the progression of colon cancer. APMIS 118(3):188-195.
55. Geiger TR, Peeper DS (2007) Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res 67(13):6221-6229.
56. Spiess C, et al. (2013) Bispecific antibodies with natural architecture produced by coculture of bacterial expressing two distinct half-antibodies. Nat Biotechnol, in press.
57. Margulies DH, Kuehl WM, Scharff MD (1976) Somatic cell hybridization of mouse myeloma cells. Cell 8(3):405-415.
58. Carter P, et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89(10):4285-4289.
59. Dennis MS (2010) Humanization by CDR repair in pharmaceutical aspects of monoclonal antibodies. Current Trends in Monoclonal Antibody Development and Manufacturing, Shire SJ, Gombotz W, Bechtold-Peters K, Andya J, eds (Association for Pharmaceutical Scientists and Springer, New York), pp 9-28.
60. Gallop MA, Barrett RW, Dower WJ, Fodor SP, Gordon EM (1994) Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J Med Chem 37(9):1233-1251.
61. Lee CV, et al. (2004) High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340(5):1073-1093.
62. Ultsch M, Lokker NA, Godowski PJ, de Vos AM (1998) Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution. Structure 6(11): 1383-1393.
63. Kirchhofer D, et al. (2004) Structural and functional basis of the serine protease-like hepatocyte growth factor β-chain in Met binding and signaling. J Biol Chem 279(38): 39915-39924.
64. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4(11):2411-2423.
65. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-325.
66. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(Pt 4):658-674.
67. Fuh G, et al. (2006) Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 281(10):6625-6631.
68. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
69. Adams PD, et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66(Pt 2): 213-221.
70. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53(Pt 3):240-255.